Summary
Biochemical and histopathological evaluations of the protective effects of the iron-chelator desferrioxamine against the cardiac and haematological toxicities of doxorubicin in normal rats were carried out. A single dose of doxorubicin (15 mg/kg, i. v.) caused myocardial damage that manifested biochemically as an elevation of serum cardiac enzyme [glutamic oxaloacetic transaminase (GOT), lactic dehydrogenase (LDH) and creatine phosphokinase (CPK)] and cardiac isoenzyme levels and histopathologically as a swelling and separation of cardiac muscle fibers. Doxorubicin caused severe leucopenia and decreases in red blood cell counts and haemoglobin concentrations at 72 h after its administration. Desferrioxamine treatment (250 mg/kg, i.p.) carried out 30 min before doxorubicin administration protected the heart and blood elements from the toxic effects of doxorubicin as indicated by the recovery of levels of cardiac enzymes and isoenzymes and of red blood cell counts to normal values and by the absence of significant myocardial lesions. The findings of this study suggest that desferrioxamine can potentially be used clinically to prevent doxorubicin-induced cardiac and haematological toxicities.
Similar content being viewed by others
References
Bachur NR, Gordon SL, Gee MV (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745–1750
Barbey MM, Fels LM, Poelstra K, Gwinner W, Bakker W, Stalte H (1989) Adriamycin affects glomerular renal function: evidence for involvement of oxygen radicals. Free Radical Res Commun 7: 195–203
Bergmeyer HU, Bernt E (1974) Lactate dehydrogenase isoenzymes. UV assay after separation on DEAE-sephadex. In: Bermeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim/Academic Press, New York London, p 590
Blum RH, Carter SL (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249–259
Bonaddona G, Monfardinin S, Lena MDE, Fossati-Bellani F (1969) Clinical evaluation of Adriamycin, a new antitumour antibiotic. BMJ: 503–506
Bristow MR (1980) Anthracycline cardiotoxicity. In: Bristow MR (ed) Drug-induced heart disease. Elsevier/North Holland, Amsterdam, pp 191–215
Calabresi P, Parks RE Jr (1982) Chemotherapy of neoplastic disease. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. Macmillan, New York Toronto London, p 1284
Dardir M, Herman EH, Ferrans VJ (1989) Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 23:269–275
David SS, Berner DL, Kasten JR, Wayne RD, William L (1984) Red and white cell count. In: Jacobs DS, Kasten RL Jr, Demott WR, Wolfson WL (eds) Laboratory test handbook with DRG index. Mosby Lexi, St. Louis, pp 326–347
El-Hage A, Herman EH, Ferrans VJ (1981) Reduction in the diabetogenic effect of alloxan in mice by pretreatment with antineoplastic agent ICRF-187. Res Commun Chem Pathol Pharmacol 33: 509–523
El-Hage A, Herman EH, Yang GC, Crouch PK, Ferrans VJ (1986) Mechanism of protective activity of ICRF-187 against alloxan-induced diabetes in mice. Res Commun Chem Pathol Pharmacol 52: 341–360
Gruiber W (1978) Inhibition of creatine kinase activity by Ca2+ and reversing effect of EDTA. Clin Chem 24: 177
Herman EL, El-Hage A, Ferrans VJ (1988) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92: 42–53
Kachmar JF, Moss DW (1982) Enzymes. In: Teitz W (ed) Fundamentals of clinical chemistry. W. B. Saunders, Philadelphia London Mexico City, pp 565–595
Klaasen CD (1982) Heavy metals and heavy metal antagonists. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. Macmillan, New York Toronto London, p 16224
Leisy SF, Milais J, Gonzales FBS, Boversis A (1990) Myocardial damage induced by doxorubicins: hydroperoxide-initiated chemiluminescence and morphology. Free Radical Biol Med 8: 259–264
Marco A, Gaetani M, Oressi P, Scardinato BM, Silvestrin R, Soldati M, Dasaia TI, Valentini L (1964) Daunomycin, a new antibiotic of the rhodomycin group. Nature 20: 706–707
Marco A, Gaetani M, Scarpinato B (1969) Adriamycin: a new antibiotic with antitumour activity. Cancer Chemother Rep 53: 33–37
Mettler FP, Young DM, Ward JM (1977) Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive failure) in rats. Cancer Res 237: 2705–2713
Minotti G, Aust SD (1989) The role of iron in oxygen radical mediated lipid peroxidation. Chem Biol Interact 71: 1–29
Myers C, Gianni L, Simone CB, Klecher R, Creene R (1982) Oxidative distruption of erythrocyte ghost membrane catalized by doxorubicin-iron complex. Biochemistry 21: 1707–1713
Olsen HM, Capen CC (1978) Chronic cardiotoxicity of Adriamycin in the rat: morphologic and biochemical investigations. Toxicol Appl Pharmacol 44: 606–616
Pannacciulli IM, Lerza RA, Boglialo GV, Mencoboni MP, Saviance AG (1980) Effect of diethyldithiocarbamate on the toxicity of doxorubicin, cyclophosphamide andcis-diamminedichloroplatinum(II) on mouse haemopoietic progenitor cells. Br J Cancer 59: 371–374
Reitman S, Frankel S (1957) A colourimetic method for determination of serum glutamic oxaloacetic and glutamic pyruvic transminase. Am J Clin Pathol 28: 56–60
Rosenoff SH, Olsen MH, Young MD, Bostick F, Young CR (1975) Brief communication: Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst 55: 191–193
Singh J, Garge KN, Garge D, Chugh K, Lal H (1989) Effect of aspartate and glutamate on experimental myocadial infarction in rats. Indian J Exp Biol 27: 621–624
Swanson JR, Wilkinson JH (1972) Measurement of creatine kinase in serum. In: Cooper GR (ed) Standard methods of clinical chemistry, vol 7. Academic Press, New York, pp 33–42
Van Jaarsveld H, Kuyl JM, Gorenewald AJ, Potgieter GM (1990) Effect of desferrioxamine on reperfusion damage of rat heart mitochondria. S Afr Med J 78: 263–265
Virgil F, Fairbanks MD (1982) Hemoglobin, hemoglobin derivatives and myoglobin. In: Tietz NW (ed) Fundamentals of clincial chemistry. W. S. Saunders, Philadelphia London Mexico City, pp 411–413
Yoda Y, Nakazawa M, Abe N, Kawakami S (1986) Prevention of doxorubicin myocardial toxocity in mice by reduced glutathione. Cancer Res 46: 2551–2556
Zbinden G, Bachmann E, Holdergger C (1978) Model system for cardiotoxic effects of anthracyclines. Antibiotic Chemother 23: 255–270
Author information
Authors and Affiliations
Additional information
This work was funded by the Research Center, College of Pharmacy, King Saud University, Via grant CPRC-43
Rights and permissions
About this article
Cite this article
Al-Harbi, M.M., Al-Gharably, N.M., Al-Shabanah, O.A. et al. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother. Pharmacol. 31, 200–204 (1992). https://doi.org/10.1007/BF00685548
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685548